Plus Therapeutics Inc. [NASDAQ: PSTV] price surged by 15.51 percent to reach at $0.38. The company report on September 1, 2020 that Plus Therapeutics, Inc. receives FDA Orphan Drug Designation for its Novel Glioblastoma Treatment.
Company Initiates Sixth Dosing Cohort in ReSPECT Trial.
Plus Therapeutics, Inc. (Nasdaq: PSTV), today announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for its lead investigational drug, Rhenium NanoLiposomes (RNL™) for the treatment of patients with recurrent glioblastoma.
A sum of 9715498 shares traded at recent session while its average daily volume was at 432.83K shares. Plus Therapeutics Inc. shares reached a high of $2.99 and dropped to a low of $2.40 until finishing in the latest session at $2.83.
The average equity rating for PSTV stock is currently 2.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Plus Therapeutics Inc. [PSTV]:
The Average True Range (ATR) for Plus Therapeutics Inc. is set at 0.28, with the Price to Sales ratio for PSTV stock in the period of the last 12 months amounting to 1.91. The Price to Book ratio for the last quarter was 3.49, with the Price to Cash per share for the same quarter was set at 2.18.
PSTV Stock Performance Analysis:
Plus Therapeutics Inc. [PSTV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.51. With this latest performance, PSTV shares gained by 8.85% in over the last four-week period, additionally plugging by 38.73% over the last 6 months – not to mention a drop of -78.82% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PSTV stock in for the last two-week period is set at 57.19, with the RSI for the last a single of trading hit 61.50, and the three-weeks RSI is set at 56.63 for Plus Therapeutics Inc. [PSTV]. The present Moving Average for the last 50 days of trading for this stock 2.49, while it was recorded at 2.50 for the last single week of trading, and 2.10 for the last 200 days.
Insight into Plus Therapeutics Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Plus Therapeutics Inc. [PSTV] shares currently have an operating margin of -52.26. Plus Therapeutics Inc.’s Net Margin is presently recorded at -46.91.
Return on Total Capital for PSTV is now -22.46, given the latest momentum, and Return on Invested Capital for the company is -93.39. Return on Equity for this stock declined to -102.83, with Return on Assets sitting at -13.91. When it comes to the capital structure of this company, Plus Therapeutics Inc. [PSTV] has a Total Debt to Total Equity ratio set at 1,032.16. Additionally, PSTV Total Debt to Total Capital is recorded at 91.17, with Total Debt to Total Assets ending up at 51.54. Long-Term Debt to Equity for the company is recorded at 55.69, with the Long-Term Debt to Total Capital now at 4.92.
Reflecting on the efficiency of the workforce at the company, Plus Therapeutics Inc. [PSTV] managed to generate an average of -$273,583 per employee. Receivables Turnover for the company is 8.28 with a Total Asset Turnover recorded at a value of 0.30.Plus Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.10.
PSTV Stock EPS
With the latest financial reports released by the company, Plus Therapeutics Inc. posted -0.03/share EPS, while the average EPS was predicted by analysts to be reported at -5.85/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 99.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PSTV.
Plus Therapeutics Inc. [PSTV] Insider Position Details
There are presently around $1 million, or 10.40% of PSTV stock, in the hands of institutional investors. The top three institutional holders of PSTV stocks are: BLACKROCK INC. with ownership of 121,038, which is approximately 0% of the company’s market cap and around 0.80% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 83,949 shares of the stock with an approximate value of $0.24 million in PSTV stocks shares; and BANK OF NEW YORK MELLON CORP, currently with $88000.0 in PSTV stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Plus Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 8 institutional holders increased their position in Plus Therapeutics Inc. [NASDAQ:PSTV] by around 38,993 shares. Additionally, 5 investors decreased positions by around 15,149 shares, while 10 investors held positions by with 226,998 shares. The mentioned changes placed institutional holdings at 281,140 shares, according to the latest SEC report filing. PSTV stock had 5 new institutional investments in for a total of 36,063 shares, while 5 institutional investors sold positions of 15,149 shares during the same period.